statistiche ricercatore

PASSAMONTI, FRANCESCO

Distribuzione geografica

Continente	#
NA - Nord America	20.257
EU - Europa	9.416
AS - Asia	2.258
SA - Sud America	20
Continente sconosciuto - Info sul continente non disponibili	12
OC - Oceania	7
AF - Africa	3
Totale	31.973

Salva come PNG Salva come JPEG

Nazione	#
US - Stati Uniti d'America	20.232
IT - Italia	5.480
UA - Ucraina	1.557
TR - Turchia	997
SE - Svezia	686
IE - Irlanda	613
VN - Vietnam	539
CN - Cina	455
DE - Germania	331
GB - Regno Unito	281
FI - Finlandia	278
SG - Singapore	168
FR - Francia	60
JP - Giappone	37
CZ - Repubblica Ceca	27
CA - Canada	21
NL - Olanda	19
HK - Hong Kong	16
ES - Italia	14
BE - Belgio	11
EU - Europa	11
RU - Federazione Russa	11
IN - India	10
AT - Austria	8
BR - Brasile	7
CL - Cile	7
BG - Bulgaria	6
MY - Malesia	6
HU - Ungheria	5
NO - Norvegia	5
TW - Taiwan	5
AU - Australia	4
IQ - Iraq	4
RS - Serbia	4
TH - Thailandia	4
BD - Bangladesh	3
CH - Svizzera	3
GR - Grecia	3
NZ - Nuova Zelanda	3
PL - Polonia	3
RO - Romania	3
SA - Arabia Saudita	3
AE - Emirati Arabi Uniti	2
AR - Argentina	2
DK - Danimarca	2
ET - Etiopia	2
IL - Israele	2
MX - Messico	2
NP - Nepal	2
PE - Perù	2
PK - Pakistan	2
SK - Slovacchia (Repubblica Slovacca)	2
A2 - ???statistics.table.value.countryCode.A2???	1
AL - Albania	1
BA - Bosnia-Erzegovina	1
EC - Ecuador	1
KR - Corea	1
KZ - Kazakistan	1
LU - Lussemburgo	1
MA - Marocco	1
MD - Moldavia	1
NI - Nicaragua	1
PA - Panama	1
PS - Palestinian Territory	1
VE - Venezuela	1
Totale	31.973

Salva come PNG Salva come JPEG

Città	#
Milan	4.198
Fairfield	3.290
Woodbridge	2.767
Houston	2.060
Ann Arbor	1.578
Ashburn	1.567
Jacksonville	1.336
Seattle	1.329
Cambridge	1.175
Wilmington	1.122
Chandler	678
Dublin	610
Princeton	525
Dearborn	479
Izmir	473
Nyköping	365
Boardman	330
Dong Ket	271
Rome	233
San Diego	176
Singapore	163
Ogden	133
Como	84
London	73
Redmond	64
Washington	63
Beijing	57
Hefei	50
Kocaeli	48
Nanjing	42
Santa Clara	35
Kunming	34
Guangzhou	32
Kilburn	29
Norwalk	29
Redwood City	25
Brno	24
Düsseldorf	21
Tokyo	21
New York	20
Chicago	19
Jinan	19
Nanchang	18
Zhengzhou	17
Verona	16
San Francisco	15
Acton	14
Changsha	12
Hong Kong	12
Shenyang	12
Baotou	11
Brussels	11
Chiswick	11
Dallas	11
Frankfurt am Main	11
Los Angeles	11
Reston	11
Chengdu	9
Falls Church	9
Fuzhou	9
Hebei	9
Hounslow	9
Munich	9
Prescot	9
Collegeville	8
Florence	8
Helsinki	8
Toronto	8
Catania	7
Indiana	7
Quzhou	7
Southwark	7
Wandsworth	7
Fayetteville	6
Hangzhou	6
Islington	6
Oxford	6
San Mateo	6
Berlin	5
Lachine	5
Memphis	5
Napoli	5
New Bedfont	5
Phoenix	5
Sapporo	5
Shanghai	5
Shaoxing	5
São Paulo	5
Vienna	5
Wenzhou	5
Wuhan	5
Amsterdam	4
Chongqing	4
Madrid	4
Ponte Lambro	4
San Jose	4
Sesto Fiorentino	4
Sofia	4
Taiyuan	4
Tappahannock	4
Totale	26.101

Salva come PNG Salva come JPEG

Nome	#
Clinical relevance of murine double minute 2 single nucleotide polymorphisms 309 in familial myeloproliferative neoplasm	257
Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study.	222
A randomized study of pomalidomide vs placebo in persons with myeloproliferative neoplasm-associated myelofibrosis and RBC-transfusion dependence	213
Which patients with myelofibrosis should receive ruxolitinib therapy? ELN-SIE evidence-based recommendations	208
Analysis of three screening methods for the detection of calreticulin gene mutations	204
Associations between gender, disease features and symptom burden in patients with myeloproliferative neoplasms: An analysis by the MPN QOL international working group	200
Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN international working group	194
Impact of ruxolitinib on the natural history of primary myelofibrosis: a comparison of the DIPSS and the COMFORT-2 cohorts	186
Hydroxyurea-related toxicity in 3,411 patients with Ph'-negative MPN	184
Blood tests may predict early primary myelofibrosis in patients presenting with essential thrombocythemia.	183
Aspirin in pregnant patients with essential thrombocythemia: a retrospective analysis of 129 pregnancies	181
New uses for brentuximab vedotin and novel antibody drug conjugates in lymphoma	177
Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study	176
JAK inhibitor therapy for myelofibrosis: critical assessment of value and limitations.	175
Bone marrow histology in marginal zone B-cell lymphomas: correlation with clinical parameters and flow cytometry in 120 patients	175
Presentation and outcome of patients with 2016 WHO diagnosis of prefibrotic and overt primary myelofibrosis	175
The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients.	174
Increased risk of lymphoid neoplasm in patients with myeloproliferative neoplasm: a study of 1,915 patients.	174
Looking for CALR mutations in familial myeloproliferative neoplasms	172
Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera	171
Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia	171
The 'GGCC' haplotype of JAK2 confers susceptibility to JAK2 exon 12 mutation-positive polycythemia vera.	170
Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients.	169
Subcutaneous 'lipoma-like' B-cell lymphoma associated with HCV infection: a new presentation of primary extranodal marginal zone B-cell lymphoma of MALT.	168
Long-term follow-up of young patients with essential thrombocythemia treated with pipobroman.	168
Mutational status of myeloproliferative neoplasms.	167
Deep sequencing reveals double mutations in cis of MPL exon 10 in myeloproliferative neoplasms	166
A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis	165
Type 1 versus Type 2 calreticulin mutations in essential thrombocythemia: A collaborative study of 1027 patients	164
Flow-FISH evaluation of telomere length in Philadelphia-negative myeloproliferative neoplasms.	164
Impact of allogeneic stem cell transplantation on survival of patients less than 65 years of age with primary myelofibrosis	164
Investigational therapies targeting lymphocyte antigens for the treatment of non-Hodgkin's lymphoma	162
Acquired copy-neutral loss of heterozygosity of chromosome 1p as a molecular event associated with marrow fibrosis in MPL-mutated myeloproliferative neoplasms	161
A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis	161
Transfusion-dependency at presentation and its acquisition in the first year of diagnosis are both equally detrimental for survival in primary myelofibrosis--prognostic relevance is independent of IPSS or karyotype.	161
Disease characteristics and clinical outcome in young adults with essential thrombocythemia versus early /prefibrotic primary myelofibrosis.	160
Altered gene expression in myeloproliferative disorders correlates with activation of signaling by the V617F mutation of Jak2	159
Calreticulin mutation does not modify the IPSET score for predicting the risk of thrombosis among 1150 patients with essential thrombocythemia	159
RBC-transfusion guidelines update	158
Mutations and thrombosis in essential thrombocythemia: Prognostic interaction with age and thrombosis history	158
Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders	155
Initial bone marrow reticulin fibrosis in polycythemia vera exerts an impact on clinical outcome.	155
Disease anticipation in familial myeloproliferative neoplasms.	155
Direct-Acting Antivirals During or After Immunochemotherapy in Hepatitis C Virus-Positive Diffuse Large B-Cell Lymphomas	155
Individualizing Care for Patients With Myeloproliferative Neoplasms: Integrating Genetics, Evolving Therapies, and Patient-Specific Disease Burden	155
European Bone Marrow Working Group trial on reproducibility of World Health Organization criteria to discriminate essential thrombocythemia from prefibrotic primary myelofibrosis: Haematologica 2012;97(3):360-5 - Comment	155
DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status.	154
Leukocytosis as an important risk factor for arterial thrombosis in WHO-defined early/prefibrotic myelofibrosis: An international study of 264 patients.	154
What are RBC-transfusion-dependence and -independence?	154
Myeloproliferative Neoplasms	154
Long term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls.	154
Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis: A Randomized Clinical Trial	154
Prognostic impact of bone marrow fibrosis in primary myelofibrosis. A study of the AGIMM group on 490 patients	154
JAK inhibitor in CALR-mutant myelofibrosis	153
Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report	152
CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons	152
How I treat polycythemia vera	151
Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs	151
TREATMENT OF POLYCYTHEMIA VERA AND ESSENTIAL THROMBOCYTHEMIA: THE ROLE OF PIPOBROMAN.	150
Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis	150
Myeloproliferative neoplasms: from JAK2 mutations discovery to JAK2 inhibitor therapies	150
Gender effect on phenotype and genotype in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis: results from the MYSEC project	150
New generation small-molecule inhibitors in myeloproliferative neoplasms	149
Health-related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinib versus best available therapy	149
Incidence and risk factors for bleeding in 1104 patients with essential thrombocythemia or prefibrotic myelofibrosis diagnosed according to the 2008 WHO criteria.	149
Patterns of presentation and thrombosis outcome in patients with polycythemia vera strictly defined by WHO-criteria and stratified by calendar period of diagnosis	149
Symptom burden profile in myelofibrosis patients with thrombocytopenia: Lessons and unmet needs	149
Antiplatelet drugs for polycythaemia vera and essential thrombocythaemia	148
European LeukemiaNet. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet.	148
MIPSS70: Mutation-Enhanced International Prognostic Score System for Transplantation-Age Patients With Primary Myelofibrosis	148
Red blood cell transfusion-dependency implies a poor survival in primary myelofibrosis irrespective of IPSS and DIPSS.	147
Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project	147
Cardiovascular events and intensity of treatment in polycythemia vera	147
The efficacy and safety of continued hydroxycarbamide therapy versus switching to ruxolitinib in patients with polycythaemia vera: a randomized, double-blind, double-dummy, symptom study (RELIEF)	147
Involvement of MAF/SPP1 axis in the development of bone marrow fibrosis in PMF patients	147
Standard care and investigational drugs in the treatment of myelofibrosis	146
It is time to change thrombosis risk assessment for PV and ET?	145
Practice-relevant revision of IPSET-thrombosis based on 1019 patients with WHO-defined essential thrombocythemia	145
A new acute myeloid leukemia case with STAT5B-RARA gene fusion due to 17q21.2 interstitial deletion	145
Exaggerated insect bite-like reaction in patients affected by oncohaematological diseases	144
ACUTE MYELOID LEUKEMIA (AML) HAVING EVOLVED FROM ESSENTIAL THROMBOCYTHEMIA (ET): DISTINCTIVE CHROMOSOME ABNORMALITIES IN PATIENTS TREATED WITH PIPOBROMAN OR HYDROXYUREA	144
Identifying and addressing unmet clinical needs in Ph-neg classical myeloproliferative neoplasms: A consensus-based SIE, SIES, GITMO position paper	143
Clinical significance of neutrophil CD177 mRNA expression in Ph-negative chronic myeloproliferative disorders	143
Essential thrombocythemia and pregnancy: Observations from recent studies and management recommendations.	143
Siltuximab and hematologic malignancies. A focus in non Hodgkin lymphoma	143
Cerebral venous thrombosis and myeloproliferative neoplasms: results from two large databases	142
A novel germline JAK2 mutation in familial myeloproliferative neoplasms	142
Clinical end points for drug treatment trials in BCR-ABL1-negative classic myeloproliferative neoplasms: consensus statements from European LeukemiaNET (ELN) and Internation Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT)	142
Blast phase of essential thrombocythemia: A single center study.	142
Bayesian models identify specific lymphoproliferative disorders associated with hepatitis C virus infection	142
Correlation of the FLIPI score for follicular lymphoma with period of diagnosis and type of treatment	141
Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT-II study	141
Leukemia risk models in primary myelofibrosis: an International Working Group study.	141
Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations.	140
Identification of genomic aberrations associated with disease transformation by means of high-resolution SNP array analysis in patients with myeloproliferative neoplasm	140
Life expectancy and prognostic factors in the classic BCR/ABL-negative myeloproliferative disorders	140
Impact of treatment-related liver toxicity on the outcome of HCV-positive non-Hodgkin's lymphomas.	140
Primary leptomeningeal CNS lymphoma presenting as bilateral facial nerve palsy	139
Dynamic International Prognostic Scoring System (DIPSS) predicts progression to acute myeloid leukemia in primary myelofibrosis.	139
Developments in diagnosis and treatment of essential thrombocythemia	139
Totale	15.918

Salva come PNG Salva come JPEG

Categoria	#
all - tutte	119.147
article - articoli	0
book - libri	0
conference - conferenze	0
curatela - curatele	0
other - altro	0
patent - brevetti	0
selected - selezionate	0
volume - volumi	0
Totale	119.147

Salva come PNG Salva come JPEG

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2019/2020	6.311	0	0	389	1.394	498	777	983	805	568	415	126	356
2020/2021	5.671	118	475	541	816	422	540	333	419	645	298	438	626
2021/2022	2.587	335	436	24	118	96	128	150	159	146	416	243	336
2022/2023	2.444	283	79	141	230	177	650	15	300	372	82	40	75
2023/2024	6.571	1.015	1.045	1.030	1.308	1.278	449	66	83	201	20	24	52
2024/2025	634	26	12	596	0	0	0	0	0	0	0	0	0
Totale													32.502